Intelligent Bio Solutions Inc SEC Filings

Intelligent Bio Solutions Inc. is implementing a 1-for-10 reverse stock split of its common stock, effective at 11:59 p.m. Eastern Time on December 15, 2025.

At the effective time, every 10 issued and outstanding shares will be combined into 1 share, with the par value remaining $0.01. As a result, common shares outstanding will decrease from approximately 9,595,335 as of December 14, 2025 to approximately 959,533 immediately after the split, while authorized common shares will stay at 100 million.

Outstanding stock options, restricted stock units, warrants and the share reserve under the 2019 Plan will be adjusted proportionately. Split-adjusted shares are expected to begin trading on The Nasdaq Capital Market on December 16, 2025 under the symbol INBS with a new CUSIP number. No fractional shares will be issued; instead, holders will receive cash based on the average closing prices over the five trading days before the split. The company also provided post-split versions of recent share and loss-per-share data.

Intelligent Bio Solutions Inc. furnished a Form 8-K announcing financial results for the fiscal quarter ended September 30, 2025. The results were communicated via a press release attached as Exhibit 99.1. The company stated that the information is furnished, not filed, and will not be incorporated by reference into other filings unless expressly stated.

Intelligent Bio Solutions Inc. (INBS) reported results for the quarter ended September 30, 2025. Revenue was $1,111,797, up from $872,287, with gross profit of $518,291 and an improved gross margin of 46.6%. Government support income was $193,267. Operating expenses rose to $3,711,151, including $2,659,824 in SG&A, $486,169 in development and regulatory costs, and a $261,780 impairment.

The company recorded a net loss of $2,994,992 (loss per share $0.35). Cash and cash equivalents were $1,660,105, with a working capital deficit of $577,705. Management stated that these conditions raise substantial doubt about the company’s ability to continue as a going concern without additional funding.

INBS raised funds via equity: $3,332,646 net from July 2025 warrant inducements and $213,750 net through its ATM program during the quarter. Warrants outstanding totaled 7,935,928. As of November 10, 2025, 9,452,553 common shares were outstanding. Management reported material weaknesses in internal control over financial reporting and disclosed Nasdaq minimum bid price compliance risk.

Intelligent Bio Solutions Inc. furnished an update on business performance, announcing preliminary, unaudited revenue results for the fiscal first quarter ended September 30, 2025. The details are provided in a press release attached as Exhibit 99.1.

The disclosure is presented as information furnished under Item 2.02 and is not deemed “filed” for purposes of the Exchange Act, nor incorporated by reference unless expressly stated.

Intelligent Bio Solutions Inc. announced the addition of 33 new customer accounts during its fiscal first quarter for the period ended September 30, 2025. The update was furnished under Item 7.01 (Regulation FD) and accompanied by a press release filed as Exhibit 99.1.

The company listed its common stock under the symbol INBS on the Nasdaq Stock Market LLC. The disclosure was signed by Spiro Sakiris, Chief Financial Officer.

Intelligent Bio Solutions (INBS) reported results from its October 16 annual meeting. Stockholders approved an amendment to the 2019 Long Term Incentive Plan, increasing the share pool by 495,000 to 1,795,000 shares. They also approved, for Nasdaq Listing Rule 5635(d) purposes, the potential issuance of up to 4,147,616 shares upon warrant exercise.

Directors were elected and the appointment of UHY LLP as auditor for the fiscal year ending June 30, 2026 was ratified. Stockholders authorized a reverse stock split within a 1‑for‑2 to 1‑for‑10 range, at the Board’s discretion within 12 months, solely to help regain compliance with the Nasdaq Capital Market minimum bid price requirement. At the meeting, 4,482,941 shares voted, representing approximately 49.65% of the 9,028,712 shares outstanding as of September 11, 2025.

INTELLIGENT BIO SOLUTIONS, INC. (INBS) filed an Form 8-K reporting a material event that attaches the Form of Amended Series H-1 Warrant as an exhibit. The filing lists Exhibit 4.1 as the amended warrant form and includes an Inline XBRL cover page data file. The document is signed by Spiro Sakiris, Chief Financial Officer.

The filing notifies stakeholders that the company has documented changes to the Series H-1 warrant in a formal amended warrant agreement, but it does not disclose the economic terms, number of warrants affected, exercise price, expiration, or any related cash or equity effects.

Intelligent Bio Solutions Inc. proxy materials disclose governance and compensation program details including an Insider Trading Policy that forbids hedging transactions by directors, officers and employees and requires compliance with applicable securities laws. The company implemented a Dodd-Frank restatement recoupment (clawback) policy effective October 2, 2023 to recoup erroneously awarded incentive compensation tied to a restatement over a defined lookback period. The filing shows an equity compensation plan with 1,192,655 shares referenced and plan provisions covering stock options, SARs, restricted stock, RSUs, transfer limits, typical vesting practices and a maximum 10-year option term (five years for >10% holders). A reverse stock split amendment is being recommended by the Board for stockholder approval. The largest disclosed shareholder is Alyeska Master Fund, LP with 927,292 shares (9.99%). Executive and director compensation snippets appear (e.g., Spiro Sakiris totals and director fees) and the Plan notes that shares to be issued are not registered under the Securities Act as of the Effective Date.